July 23, 2014 / 2:31 PM / 3 years ago

Inovio Pharma's drug to treat cervical lesions meets trial goal

(Reuters) - Inovio Pharmaceuticals Inc said its drug to treat abnormal growth of pre-cancerous cells on the surface of the cervix met its main goal in a mid-stage trial.

Inovio shares jumped 27 percent to a three-month high of $14.14 on the American Stock Exchange. They were up 23.5 percent at $13.78 in morning trade.

The pre-cancerous cells, commonly know as cervical dysplasia, are caused by the human papillomavirus (HPV), a sexually transmitted disease. Left untreated, the condition can sometimes worsen to an early form of cancer.

The drug, code named VGX-3100, was effective in treating pre-cancerous cervical disease and cleared HPV infection, the company said.

Reporting by Anand Basu; Editing by Don Sebastian

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below